Orchid Pharma Ltd. (ORCHPHARMA): Orchid Pharma Share Price Rises 5.13% Today: Key Levels
- September 9, 2026
- Posted by: Harsh Piplani
- Category: News
Orchid Pharma Share Price rose 5.13% to Rs 1,017.25, adding Rs 49.60 from the previous close of Rs 967.65. The company’s market capitalisation stood at Rs 5,668.13 Cr, placing the move squarely in today’s Orchid Pharma Share Price Today and Orchid Pharma Stock News conversation. According to latest Univest data, the price action confirms a clear intraday share price rise, while the latest Univest figures do not establish a company-specific catalyst. That makes the stock relevant mainly on market action, valuation and healthcare-sector context. Investors tracking Orchid Pharma Share Price can therefore focus on how the move compares with its current earnings multiples, broader sector positioning and the next market update on the counters that are drawing attention in Indian Stock Market trade.
Orchid Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,017.25 |
| Previous Close | Rs 967.65 |
| Today's Move | Rs 49.6 (+5.13%) |
| Open | Rs 975 |
| High | Rs 1,023.75 |
| Low | Rs 969.45 |
| Turnover | Rs 0.6 crore |
| Market Capitalisation | Rs 5,668.13 crore |
| Market Cap Category | Mid Cap |
Orchid Pharma Ltd. (ORCHPHARMA) rose to Rs 1,017.25 from the previous close of Rs 967.65, a move of Rs 49.6 or 5.13%. The stock opened at Rs 975, reached a high of Rs 1,023.75, recorded a low of Rs 969.45.
Orchid Pharma Share Price Today opened at Rs 975.00, moved between Rs 969.45 and Rs 1,023.75, and last traded at Rs 1,017.25. The stock gained Rs 49.60, or 5.13%, from the previous close, and turnover was Rs 0.6 Cr. In price-action terms, the move shows buyers were willing to lift the stock above the opening print and keep it near the upper end of the day’s range. For readers following Orchid Pharma Stock News, this is a straightforward price rise rather than a story with a verified trigger. The latest Univest figures show Orchid Pharma Share Price holding above the prior close and trading with active interest in today’s Share Market Today move.
Orchid Pharma Ltd. (ORCHPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 5,668.13 crore |
| P/E Ratio | 668.68x |
| P/B Ratio | 4.46x |
| ROE | 7.86% |
| ROCE | 8.05% |
| EPS | Rs 1.45 |
| Book Value Per Share | Rs 217 |
| Dividend Yield | 0% |
Orchid Pharma Ltd. (ORCHPHARMA) fundamental metrics show P/E 668.68x, P/B 4.46x, ROE 7.86%, ROCE 8.05%. These figures provide context only and are not a buy or sell signal.
Orchid Pharma Ltd. has a market capitalisation of Rs 5668.13 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 668.68x, P/B at 4.46x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 7.86% and ROCE of 8.05%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 1.45, book value per share of Rs 217, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.19x, median ROE of 11.82%, median ROCE of 13.71%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 668.68x |
| Benchmark Median P/E | 32.19x |
| Benchmark Average P/E | 49.13x |
| Benchmark P/E Range | 3.39x to 668.68x |
| Company P/B Ratio | 4.46x |
| Benchmark Median P/B | 3.05x |
| Company ROE | 7.86% |
| Benchmark Median ROE | 11.82% |
| Company ROCE | 8.05% |
| Benchmark Median ROCE | 13.71% |
| Company Market Capitalisation | Rs 5,668.13 crore |
| Benchmark Median Market Cap | Rs 715.6 crore |
Orchid Pharma Ltd. (ORCHPHARMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Orchid Pharma Ltd. (ORCHPHARMA) has a P/E ratio of 668.68x, which is above the benchmark median of 32.19x, a difference of +1,977.29%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Orchid Pharma Ltd. (ORCHPHARMA) has a ROE of 7.86%, which is below the benchmark median of 11.82%, a difference of -33.5%. Orchid Pharma Ltd. (ORCHPHARMA) has a ROCE of 8.05%, which is below the benchmark median of 13.71%, a difference of -41.28%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,55,825.66 | 37.31 | 5.22 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,47,018.51 | 86.86 | 14.38 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,86,874.73 | 86.55 | 21.03 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,211.69 | 25.42 | 4.25 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,12,773 | 33.17 | 3.18 | 11.83 | 16 |
Orchid Pharma Ltd. (ORCHPHARMA) has a P/E ratio of 668.68x compared with the displayed peer median of 37.31x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 7.86% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 8.05% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Orchid Pharma Ltd. (ORCHPHARMA) has a market capitalisation of Rs 5,668.13 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Orchid Pharma
- Orchid Pharma Share Price is up 5.13% today, with the stock last traded at Rs 1,017.25.
- The move is notable because Orchid Pharma Stock News currently has no verified company-specific catalyst in the latest Univest figures.
- Valuation is a key watchpoint, with P/E at 668.68 and P/B at 4.46.
- Return ratios remain modest, with ROE at 7.86% and ROCE at 8.05%.
- The stock is being tracked inside Healthcare and Pharmaceuticals & Drugs alongside larger peers with very different multiples.
About Orchid Pharma
Orchid Pharma Ltd. is part of the Pharmaceuticals & Drugs industry in the Healthcare sector. The company’s listed profile places it within the Indian pharmaceutical universe, where investors usually compare market cap, valuation ratios, return metrics and sector standing. Orchid Pharma Share Price matters to market participants because the stock is trading at a level where earnings multiples, book value and capitalisation all need to be read together. With a market cap of Rs 5,668.13 Cr, the company sits above the median industry size but below many large listed pharma names.
That is why Orchid Pharma Share Price Today often draws both stock-market traders and long-term investors who follow Orchid Pharma Stock Analysis, Orchid Pharma Share News and Orchid Pharma Latest News on Univest. The company’s place in healthcare also means it remains part of broader sector watching when market participants assess Indian Stock Market themes.
Frequently Asked Questions
Why is Orchid Pharma Share Price rising today?
Ans. Orchid Pharma Share Price rose 5.13% to Rs 1,017.25, but the latest Univest data does not establish a company-specific catalyst. The move is confirmed as a same-day price rise, so investors should focus on market action and valuation.
What is Orchid Pharma Share Price today?
Ans. Orchid Pharma Share Price Today is Rs 1,017.25. The stock added Rs 49.60 from the previous close of Rs 967.65, making it one of the notable movers in Healthcare during today’s trade.
How much did Orchid Pharma stock gain today?
Ans. Orchid Pharma stock gained 5.13% today. In rupee terms, the share price moved up by Rs 49.60, reflecting a clear intraday rise from the previous close and stronger buying interest during the day.
What is Orchid Pharma’s market capitalisation?
Ans. Orchid Pharma’s market capitalisation stood at Rs 5,668.13 Cr. That places it above the median market cap in its industry benchmark, though still far below the largest healthcare peers listed on Univest.
Is Orchid Pharma expensive on valuation?
Ans. Orchid Pharma trades at a P/E of 668.68, which is well above the industry median of 32.19 and average of 49.13. Its P/B of 4.46 is closer to the sector average, but earnings valuation is elevated.
How does Orchid Pharma compare with healthcare peers?
Ans. Orchid Pharma’s P/E is much higher than Sun Pharma, Cipla, Zydus Lifesciences, Divi’s Laboratories and Torrent Pharmaceuticals. Its ROE and ROCE are also lower than those peers in the latest Univest comparison.
What do Orchid Pharma EPS and book value show?
Ans. Orchid Pharma reports EPS of Rs 1.45 and book value of Rs 217. EPS reflects earnings per share, while book value shows accounting net worth per share. Together, they help explain the current Orchid Pharma Share Price.
Should investors track Orchid Pharma Share Price on Univest?
Ans. Yes, investors tracking Orchid Pharma Share Price can use Univest to follow price updates, valuation ratios, sector context and peer comparison. The stock’s 5.13% rise makes it relevant for market-watch lists today.
Track Orchid Pharma Share Price on Univest
Use Orchid Pharma Ltd. (ORCHPHARMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Track Orchid Pharma Share Price Live on Univest for updates on price, market cap, valuation ratios, sector view and company-level market insights. Users can also follow Orchid Pharma Share Price Today, Orchid Pharma Stock News and Orchid Pharma Share Price Update through the stock page and related analysis tools on Univest.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
